Indication
HER2-positive Advanced Breast Cancer
4 clinical trials
7 products
1 drug
Clinical trial
A Multicentre, Randomized, Open-label, Controlled Phase Ш Clinical Study to Evaluate the Efficacy and Safety of DP303cversus Trastuzumab Combined With Vinorelbine/Capecitabine in of HER2-positive Advanced Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Product
CapecitabineProduct
DP303cProduct
VinorelbineClinical trial
Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous Chimeric Receptor T Cells in HER2+ Advanced Breast Cancer and Other Solid TumorsStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in the Treatment of Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2027-12-31
Product
InetetamabDrug
TrastuzumabClinical trial
Phase II Clinical Study of Trastuzumab Emtansine (T-DM1) Combined With Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Ribociclib in the Treatment of Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Advanced Breast CancerStatus: , Estimated PCD: 2027-01-10
Product
Ribociclib